Where was the research reported? The study on meningococcal C vaccine in infants, was reported in the Lewiston Morning tribune on June 07, 2000, page: 2A, the author stated this was a wire service report. The Journal of the American Medical Association printed "Safety, Immunogenicity, and Induction of Immunologic memory by Serogroup C Meningococcal Conjugate Vaccine in Infants," on June 07, 2000, p 2795-2801. This report was authored by the following people: Jenny Maclennan, Fiona Shackley, Paul Heath, Jonathan J.Deeks, Caroline Flamank, Mark Herbert, Helen Griffiths, Eva Hatzmann, Christian Goilav, and Richard Moxon. I can judge the article as having been written by knowledgeable authors, according to their affiliations.
What is the causal hypothesis? The causal hypothesis is that meningococcal C conjugate vaccine will prevent infants from contracting bacterial meningitis. Around half of all cases of meningococcal disease occurs in children younger than 5 years with the highest attack rates in children younger than 2 years.
The antibody results indicate that these meningococcal C vaccines are highly immunogenic and able to induce primary response and immunologic memory in young infants. Meningococcal C bacteria causes about one-third of the 3,000 U.S cases of meningococcal disease each year. Meningococcal disease can cause bacterial meningitis, which is a fatal bloodstream infection.
What kind of causal experiment was undertaken? The causal experiment was undertaken as a randomized controlled trail in 1995 and 1996. This experiment has a single-center, double-blind design. Subjects are divided into two experimental groups prior to the experiment and only the experiment subjects are exposed to the suspected causal agent. Group one is given the vaccine meningococcal C1, group two is given meningococcal (C-2), while the control group was given (HVB) hepatitis B vaccine. In twelve months all three groups received a booster (MPS) or a different type of booster. MPS...